Clinical Trial Detail

NCT ID NCT03150810
Title Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors BeiGene

triple-receptor negative breast cancer

lung small cell carcinoma

stomach cancer

ovarian cancer

Advanced Solid Tumor

prostate cancer


Pamiparib + Temozolomide

Age Groups: senior adult

No variant requirements are available.